TECH vs MESO

For growth investors, Mesoblast Limited (MESO) is the stronger pick with 191.

4% revenue growth year-over-year, versus 5. 2% for Bio-Techne Corporation (TECH). Bio-Techne Corporation (TECH) offers the better valuation at 110. 7x trailing P/E (25. 7x forward), making it the more compelling value choice. Analysts rate Bio-Techne Corporation (TECH) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Mesoblast Limited (MESO) delivered a total return of +6.

0%, compared to -50. 3% for Bio-Techne Corporation (TECH). Over 10 years, the gap is even starker: TECH returned +112. 5% versus MESO's -2. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Techne Corporation (TECH) is the lower-risk stock at 1.

41β versus Mesoblast Limited's 1. 70β — meaning MESO is approximately 20% more volatile than TECH relative to the S&P 500. On balance sheet safety, Mesoblast Limited (MESO) carries a lower debt/equity ratio of 21% versus 23% for Bio-Techne Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Mesoblast Limited (MESO) is pulling ahead at 191.

4% versus 5. 2% for Bio-Techne Corporation (TECH). On earnings-per-share growth, the picture is similar: Mesoblast Limited grew EPS 5. 6% year-over-year, compared to -56. 2% for Bio-Techne Corporation. Over a 3-year CAGR, MESO leads at 19. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Techne Corporation (TECH) is the more profitable company, earning 6.

0% net margin versus -593. 9% for Mesoblast Limited — meaning it keeps 6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TECH leads at 8. 4% versus -363. 1% for MESO. At the gross margin level — before operating expenses — MESO leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for TECH: 36.

2% to $69. 33.

In this comparison, TECH (0.

6% yield) pays a dividend. MESO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bio-Techne Corporation (TECH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0.

6% yield, +112. 5% 10Y return). Mesoblast Limited (MESO) carries a higher beta of 1. 70 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TECH: +112. 5%, MESO: -2. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TECH is a small-cap quality compounder stock; MESO is a small-cap high-growth stock. TECH pays a dividend while MESO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.